**Question:** Leflunomide used against Rheumatoid arthritis acts by inhibiting:

**Core Concept:** Leflunomide is a medication primarily used in the treatment of Rheumatoid Arthritis (RA). It belongs to a class of drugs called Disease-Modifying Anti-Rheumatic Drugs (DMARDs), which aim to slow down the progression of RA and reduce joint damage.

**Why the Correct Answer is Right:** Leflunomide works by inhibiting the enzyme dihydroorotate dehydrogenase (DHODH), which is involved in pyrimidine synthesis in the mitochondria of activated immune cells. By suppressing pyrimidine synthesis, leflunomide reduces the proliferation of activated immune cells, particularly T-cells and B-cells, that play a significant role in the inflammation of RA. This leads to a decrease in pro-inflammatory cytokines and overall suppression of the immune system, ultimately benefiting RA patients.

**Why Each Wrong Option is Incorrect:**

A. Leflunomide does not inhibit Cyclooxygenase (COX) enzymes, which are responsible for inflammation and pain in RA. Inhibition of COX enzymes is the primary mechanism of action for Nonsteroidal Anti-Inflammatory Drugs (NSAIDs) like ibuprofen, which are used for pain relief in RA but not for disease modification like leflunomide.

B. Leflunomide does not inhibit Interleukin-6 (IL-6) production. IL-6 is a pro-inflammatory cytokine involved in RA pathogenesis, but its inhibition is not the primary mode of action for leflunomide.

C. Leflunomide does not selectively inhibit Cyclic Adenosine Monophosphate (cAMP) production. While cAMP plays a role in immune cell activation, the primary focus of leflunomide is on immune cell proliferation inhibition rather than cAMP modulation.

D. Leflunomide does not selectively inhibit Cyclic Guanosine Monophosphate (cGMP) production. While cGMP is involved in immune cell activation, the primary mode of action for leflunomide is the suppression of immune cell proliferation, not cGMP inhibition.

**Clinical Pearl:** Leflunomide's primary mode of action lies in its inhibition of pyrimidine synthesis via DHODH, which directly targets the proliferation of activated immune cells involved in RA pathogenesis, making it a more specific and effective treatment than nonsteroidal anti-inflammatory drugs (NSAIDs) like ibuprofen, which primarily alleviate pain but do not modify the disease progression.

**Core Concept:** Leflunomide, a potent immunosuppressive drug, is used in the treatment of autoimmune disorders like RA, where an overactive immune system causes inflammation and joint damage. The drug's primary mode of action involves the inhibition of pyrimidine synthesis, which results in the suppression of activated immune cells involved in RA pathogenesis.

**Why Leflunomide is more effective in RA treatment:** Leflunomide is more effective in RA treatment because it specifically targets the activated immune cells that are driving the disease progression. In contrast